Newborn Calf Serum Market, By Origin (New Zealand Origin, U.S. Origin, Australia Origin, and Others (Brazil Origin, Mexico Origin, etc.)), By Application (Drug Discovery, Cell Media Culture, and Others), By End User (Biotechnology & Pharmaceutical Industries, Academic Institutes, and Others (Research labs and Diagnostic Labs, etc.)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5331

Pages :420

Formats :

Excel and PDF

Industry : Biotechnology

Newborn Calf Serum MarketSize and Trends

Global Newborn Calf Serum Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive the growth of the global newborn calf serum market, owing to an increase in research and development activities related to vaccine production. For instance, in 2020, Bharat Biotech, a biotechnology company, had conducted research for the production of COVID-19 vaccine, in which newborn calf serum was used as one of the key ingredient for growing the vero cells lines. These cell lines were used in the manufacturing process of vaccines. Cell culture is done for testing the capacity, nature, etc. of vaccine agents.

Increasing in number of clinical trials for new drug discovery, after COVID-19, is expected to drive the growth of the global newborn calf serum market over the forecast period. For instance, in 2020, Frontiers journal published a review article on clinical trials done after COVID-19. According to the published data, there was a great increase in clinical trials for the development of new drugs. Before clinical trials new drugs are tested on cell lines, these cell lines are grown with the use of serum, as one of the key ingredient in growing medium. Increasing number of clinical trials indicates use of cell lines in large amount, which is expected to increase the use of new born calf serum.

The global newborn calf serum market is estimated to be valued at US$ 222.2 Mn in 2022 and is expected to exhibit a CAGR of 6.8% over the forecast period (2022-2030).

Figure 1: Global Newborn Calf Serum Market Share, (%), Analysis, By Origin, 2022

Pharmaceutical companies have started investing in the production of newborn calf serum. This is expected to propel the growth of the global newborn calf serum market over the forecast period.

Market players are investing in manufacturing unit to increase their manufacturing capacity, this is expected to drive the growth of global newborn calf serum market. For instance, in January 2018, Indian Immunologicals Limited, an animal and human vaccine manufacturer started its new manufacturing plant with wholly owned its subsidiary Pristine Biologicals (NZ) Ltd. in New Zealand with the investment of US$1 million. Among all the product, newborn calf serum is one of the key product manufactured by this new manufacturing plant. Indian Immunological Limited as invested in this because it want a control over the key ingredient used for the manufacturing of vaccines.

Key players are involved in expanding their services for cell therapy, which is expected to drive the growth of the global newborn calf serum market over the forecast period.

Newborn calf serum is a key ingredient in cell culture. Market players are investing in large scale in cell culture research. Companies are expanding their services toward cell therapy, therefore, these factors are expected to increase the use of newborn calf serum in future which will boost the growth of global newborn calf serum market. For instance, in June 2022, NorthX Biologics, a biologics company with the help of Alder Therapeutics, a pharmaceutical company expanded its services for cell therapy and established Good Manufacturing Practice (GMP)-manufacturing labs at Matfors facility and Karolinska University Hospital campus in Stockholm. NorthX is doing this expansion due to increasing needs of patients and growing cell therapies market.